B1NT34

BioNTech SE | Cotação de Ações

Última atualização26/12/2024, 14:44:53

PreçoR$ 44,13

Variação (dia)R$ 0,25 (0.57%)▲

Min. 52 SemanasR$ 26,80

Máx. 52 SemanasR$ 47,40

Capitalização de mercado--

Endereço: An der Goldgrube 12, Mainz, 55131

Telefone: 49 6131 9084 0

Funcionários: 6.133

BIONTECH SE DRNB1NT34

R$ 44,13

+ 0,250,57%

26/12/2024 14:44:53

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualR$ 44,13

Valor de mercado--

AberturaR$ 44,52

Preço máximoR$ 44,37

Preço mínimoR$ 41,81

VolumeR$ 70

Fechamento anteriorR$ 43,88

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vaccine ecosystem. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Ações relacionadas

Pfizer Inc.

PFIZ34 ▼0.27% | R$ 41,11

Moderna, Inc.

M1RN34 ▲0.87% | R$ 12,97

Tesla, Inc.

TSLA34 ▲3.50% | R$ 87,00

AstraZeneca PLC

A1ZN34 ▼0.63% | R$ 68,29

Alphabet Inc.

GOGL34 ▲0.73% | R$ 100,99

Saiba mais sobre a brapi e nossa missão de fornecer informações confiáveis

Entenda a missão da brapi em fornecer informações estritamente informativas de fontes confiáveis. Valorizamos a transparência e a responsabilidade, incentivando investidores a buscar aconselhamento financeiro independente para decisões informadas.

Conheça os Planos e Preços personalizados para acessar recursos exclusivos

Explore nossos Planos e Preços para obter acesso a recursos exclusivos, atendendo às suas necessidades específicas. Oferecemos opções flexíveis para investidores de todos os níveis, garantindo que você tenha as ferramentas certas para otimizar sua estratégia de investimento.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.